CTIS2023-504577-21-00
Active, not recruiting
Phase 1
A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatment. - CLADRI_NET
María Luisa Martínez Ginés0 sites20 target enrollmentMarch 23, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- María Luisa Martínez Ginés
- Enrollment
- 20
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •MS diagnostic following McDonald 2010 diagnosis criteria., Age between 30 and 55 years old., MS patients that started treatment with cladribine tablets in the last month., Consent form signature
Exclusion Criteria
- •Dementia diagnosis, following Spanish Neurological Society criteria., Mayor psychiatric illness., Physical or intellectual limitations to successfully perform neuropsychological evaluation., Any other circumstance that may interfere with functional magnetic resonance session, Abnormal renal function previous to MRI session., Pregnant or breastfeeding females or males and females of childbearing potential not willing to use a medically acceptable contraceptive method from enrolment until six months after the end of the treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in patients with cutaneous lesions in scleroderma diseases.Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases.MedDRA version: 20.0Level: HLTClassification code 10039711Term: Scleroderma and associated disordersSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2015-005100-28-ITMASTELLI SR45
Completed
Phase 4
A clinical study to see the effect and safety of Phenocaine Plus Injection in Cataract Surgery.Health Condition 1: H28- Cataract in diseases classified elsewhereCTRI/2021/04/032545Entod Pharmaceuticals Ltd
Completed
Phase 4
A Phase IV, monocentric, clinical trial to evaluate and compare the number of nicks and cuts among three different shaving systems on healthy Indian men.CTRI/2011/07/001890Procter and Gamble50
Active, not recruiting
Not Applicable
Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®.Healthy volunteers (Vaccination against hepatitis A in healthy adults)MedDRA version: 16.1Level: LLTClassification code 10052551Term: Hepatitis A virusSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-001918-15-BEGlaxoSmithKline Biologicals
Active, not recruiting
Not Applicable
A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysisHyperphosphataemia in patients with chronic kidney disease stage 5 receiving haemodialysisMedDRA version: 8.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2006-003364-64-ATShire Pharmaceutical Development Ltd760